FDA Grants Priority Review to Zanidatamab for HER2+ Metastatic Biliary Tract Cancer

Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.

Related Keywords

Kaplan Meier ,Rob Iannone ,Jazz Pharmaceuticals ,Prescription Drug User Fee Act ,Lancet Oncology ,